Genomic & Biopharma News

Upstart Blade nabs Bristol-Myers Squibb research executive as new R&D lead
Blade Therapeutics is looking to sharpen its focus after hiring Bristol-Myers Squibb’s former fibrosis research lead as its new EVP of research. The biotech, which is working on antifibrotic (scarring) therapies, has appointed Maria E. Fuentes, Ph.D., to lead its antifibrotic programs in preclinical testing.
Fierce Biotech, 2017-08-21 12:19:43

New vaccine could offer protection against opioid combinations
Substance abuse is a continuing problem in the U.S., particularly with heroin and other opioids, to the point of being an epidemic.
News Medical Life Sciences, 2017-08-21 12:05:04

Walnuts reduce hunger by activating a certain brain region, say researchers
Scientists have shown that eating walnuts activates a region of the brain involved in the control of hunger and food cravings, which could explain why people report feeling full after eating them.
News Medical Life Sciences, 2017-08-21 12:05:00

Palm Beach Post: ORB Leaves Palm Beach County for New Lab Space
David Willoughby lives in Palm Beach Gardens and, until recently, worked there too. But the owner of Ocean Ridge Biosciences wanted to expand, and he couldn't find suitable space in northern Palm Beach County.
ORB Company News, 2016-12-02 15:35:33

SLAM-seq – Thiol-linked alkylation for the metabolic sequencing of RNA
Gene expression profiling by high-throughput sequencing reveals qualitative and quantitative changes in RNA species at steady-state but obscures the intracellular dynamics of RNA transcription, processing and decay. Researchers at the Institute of Molecular Biotechnology, Vienna have developed thiol(SH)-linked alkylation for the metabolic sequencing of RNA (SLAM-seq), an orthogonal chemistry- based epitranscriptomics-sequencing technology that uncovers 4-thiouridine (s4U)- incorporation ...
Transcriptome Research & Industry News, 2017-08-21 12:03:54

New CEO takes the helm at Akari as it tries to navigate choppy waters
Former Zealand Pharma chief David Horn Solomon, M.D., has taken up the challenge of guiding biotech Akari during an increasingly tumultuous period.
Fierce Biotech, 2017-08-21 12:01:10

Identification of an lncRNA‑miRNA‑mRNA interaction mechanism in breast cancer
Non‑coding RNAs serve important roles in regulating the expression of certain genes and are involved in the principal biological processes of breast cancer. The majority of studies have focused on defining the regulatory functions of long non‑coding RNAs (lncRNAs) and microRNAs (miRNAs/miRs), and few studies have investigated how lncRNAs and miRNAs are transcriptionally regulated. In ...
lncRNA Research and Industry News, 2017-08-21 11:35:46

Palm Beach Post: ORB Leaves Palm Beach County for New Lab Space
David Willoughby lives in Palm Beach Gardens and, until recently, worked there too. But the owner of Ocean Ridge Biosciences wanted to expand, and he couldn't find suitable space in northern Palm Beach County. Please read the PDF for more details
ORB Company News, 2016-12-02 15:35:33

Antibiotic-induced release of exosomes with surface-associated DNA
Recently, biological roles of extracellular vesicles (which include among others exosomes, microvesicles and apoptotic bodies) have attracted substantial attention in various fields of biomedicine. Here, researchers at Semmelweis University investigated the impact of sustained exposure of cells to the fluoroquinolone antibiotic ciprofloxacin on the released extracellular vesicles. Ciprofloxacin is widely used in humans against bacterial ...
Exosome RNA Research & Industry News, 2017-08-21 11:23:25

Samsung jumps into novel drug R&D through Takeda deal
Samsung Bioepis has begun its long-anticipated move into novel drug R&D. The offshoot of South Korean conglomerate Samsung is taking its first steps beyond the lower risk, lower reward world of biosimilars by teaming up with Takeda to co-develop drugs against diseases including pancreatitis.
Fierce Biotech, 2017-08-21 11:16:47

Poly-A selection or Ribo-depletion?
RNA sequencing (RNA-seq) has become an indispensable tool to identify disease associated transcriptional profiles and determine the molecular underpinnings of diseases. However, the broad adaptation of the methodology into the clinic is still hampered by inconsistent results from different RNA-seq protocols and involves further evaluation of its analytical reliability using patient samples. Here, researchers at ...
Transcriptome Research & Industry News, 2017-08-21 11:05:00